Withdrawal of Registration Statement (rw)
November 20 2015 - 11:28AM
Edgar (US Regulatory)
StemGen, Inc.
800 Town and Country Blvd., Suite 300
Houston, Texas 77024
November 20, 2015
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: | Pamela A. Long, Assistant Director |
| Edward M. Kelly, Senior Counsel Craig E. Slivka, Special Counsel Terence S. O'Brien, Accounting Branch Chief Tracey L. McKoy, Staff Accountant |
Ladies and Gentlemen:
Pursuant to Rule 477 under the Securities Act of 1933, as amended, StemGen, Inc. hereby requests that the Securities and Exchange Commission consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the registrant's registration statement on Form S-1, File Number 333-202814, together with all exhibits thereto (collectively, and as amended, the "Registration Statement"). The Registration Statement was initially filed with the Commission on March 17, 2015.
At this time the registrant has not progressed sufficiently with the execution of its business plan to justify the secondary shelf registration statement. The Registration Statement has not been declared effective by the Commission and the registrant hereby confirms that no securities were sold in connection with the offering described in the Registration Statement.
Accordingly, we request that the Commission issue an order granting the withdrawal of the Registration Statement effective as of the date hereof or at the earliest practicable date hereafter. The registrant further requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.
Please send a copy of the order granting the withdrawal to the undersigned at 800 Town and Country Blvd., Suite 300, Houston, Texas 77024 or via email at David@StemGenIncorporated.com with a copy to our legal counsel, Robert L. Sonfield, Jr. of Sonfield & Sonfield, via email: robert@sonfield.com.
If you have any questions regarding this application, please contact Robert L. Sonfield, Jr. of Sonfield & Sonfield by telephone at (713) 877-8333 or by email at robert@sonfield.com. Thank you for your attention to this matter.
Yours very truly
/s/ John David Walls | |
John David Walls | |
Chief Executive Officer and Director | |
Cc: | Robert L. Sonfield, Jr. | |
| Sonfield & Sonfield | |
StemGen (CE) (USOTC:SGNI)
Historical Stock Chart
From Mar 2024 to Apr 2024
StemGen (CE) (USOTC:SGNI)
Historical Stock Chart
From Apr 2023 to Apr 2024